|
Author Archive: AZBio
The Honorable Jane Dee Hull will be honored with the AZBio Pioneer Award for Lifetime Achievement at the 2019 AZBio Awards
CHANDLER, Ariz — (BUSINESS WIRE) — The Arizona Bioindustry Association (AZBio) today announced that The Honorable Jane Dee Hull, 20th Governor of the State of Arizona will be honored on October 2, 2019 with the AZBio Pioneer Award for Lifetime Achievement at the AZBio Awards.
The AZBio Pioneer Award for Lifetime Achievement is the highest honor awarded by Arizona’s bioscience community and is extended to an Arizonan whose body of work has made life better for people at home and around the world.Continue reading
New ‘liquid biopsy’ blood test improves breast cancer diagnostics
In a new study, Biodesign teams up with the Translational Genomics Research Institute (TGen) and the Mayo Clinic in Arizona present a blood-based cancer monitoring test known as TARDIS, which improves the sensitivity of such tests by 100 times or more. Continue reading
Meet MAT
Pharmaceutical Research and Manufacturers of America (PhRMA) created the Medicine Assistance Tool (MAT) to provide a dedicated search engine that allows users to search for financial assistance resources available to them, their loved ones or patients in their lives through the various biopharmaceutical industry programs available for patients who are eligible.Continue reading
During National Immunization Awareness Month, Arizona Professional Organizations and Citizens Urge Action to Improve Childhood Vaccination Rates
Health Advocates visit the Arizona Capitol to share important messages.Continue reading
Follow The Pill
Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen. However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine. To help put this debate into context, here is a new educational video that helps explain how prescription drug costs are really determined and where the pharmaceutical dollar actually goes.Continue reading
New study reviews unregulated stem cell clinics in six SW states
Expertise of providers, legitimacy of therapies examined
Aug. 1, 2019, Tempe, Arizona — Unproven and unregulated stem cell therapies for treatments for conditions ranging from Parkinson’s disease to multiple sclerosis to macular degeneration are putting patients at risk in a market that has grown rapidly in recent years.Continue reading
UA Researcher and Doctoral Student Reconcile Scientific Standoff in Colon Cancer Research
Curtis Thorne, PhD, and UA doctoral student Carly Cabel validated findings from a 2018 collaborative study that identified a possible new therapeutic target for colon cancer – after a Harvard lab challenged the initial results.Continue reading
Castle Biosciences IPO raises $73.6 Million
Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares.
Castle Biosciences is a commercial-stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.
The company is headquartered in Friendswood, Texas and has Laboratory/Clinical Operations in Phoenix, Arizona.